N
STSA

Nuveen’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Nuveen’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-35,379
Closed -$826K – 3588
2021
Q1 		$826K Buy
35,379
+334
+1% +$2.02K ﹤0.01% 2953
2020
Q4 		$818K Sell
35,045
-20,774
-37% -$89.5K ﹤0.01% 2878
2020
Q3 		$1.3M Buy
55,819
+18,925
+51% +$380K ﹤0.01% 2572
2020
Q2 		$1.06M Buy
36,894
+26,031
+240% +$603K ﹤0.01% 2603
2020
Q1 		$234K Buy
+10,863
New +$247K ﹤0.01% 2970

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen's STSA Position: Q2 2021 in Review

Nuveen sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2021, closing a stake of 35,379 shares — an estimated $826K sold.

Nuveen first reported a position in STSA in Q1 2020 and held it in 5 quarters. The position peaked at $1.3M in Q3 2020. 60 funds tracked by Wall St. Rank hold STSA as of Q2 2021.

  • Nuveen reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Nuveen sold 35,379 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $826K.
  • Nuveen first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
  • Nuveen's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $1.3M in Q3 2020.
  • 60 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.